Plasma concentrations and central nervous system effects of the new hypnotic agent zopiclone in patients with chronic liver disease.
Authors:
- G ParkerGPG Parker
- Cj RobertsCRCj Roberts
Open Access
- 1 September 1983
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 16 (3) , 259-265
Abstract
Eight healthy individuals and seven cirrhotic patients received 7.5 mg zopiclone orally. Two further cirrhotics received 3.75 mg. Plasma concentrations of zopiclone and psychometric tests including reaction time and critical flicker fusion threshold and electroencephalographic tracings were performed at regular intervals after drug administration. Peak plasma levels of zopiclone were similar in the two groups but the time to peak was delayed in the cirrhotics. Plasma zopiclone half-life was 8.53 +/- 0.83 h in the cirrhotics and 3.50 +/- 0.33 h in the healthy individuals. In the group of cirrhotics there was a negative correlation between zopiclone half-life and serum albumin concentration (r = -0.87). Zopiclone caused sedation in both groups. Reaction time was prolonged and critical flicker fusion threshold reduced in both groups. Recovery was delayed in the cirrhotics compared to the healthy subjects but was complete by 8 h. The size of the changes was somewhat greater in the cirrhotics but baseline observations differed between the groups. The mean dominant frequency was lower in the cirrhotics and fell slightly in that group after zopiclone administration. The response to zopiclone is delayed and exaggerated in cirrhosis. Precautions are therefore required when using this drug in patients with chronic liver disease.Keywords
This publication has 19 references indexed in Scilit:
- Effects of cirrhosis and ageing on the elimination and bioavailability of ranitidine.Gut, 1982
- Psychomotor function and psychoactive drugs.British Journal of Clinical Pharmacology, 1980
- Hepatic Disease and Drug PharmacokineticsClinical Pharmacokinetics, 1980
- Hepatic First-pass Metabolism in Liver DiseaseClinical Pharmacokinetics, 1979
- Decreased first-pass metabolism of labetalol in chronic liver disease.BMJ, 1978
- Effect of cirrhosis of the liver on the pharmacokinetics of chlormethiazole.BMJ, 1978
- Intravenous administration of diazepam in patients with chronic liver disease.Gut, 1976
- Medium chain triglycerides and hepatic encephalopathyGut, 1974
- Determinants of serum antipyrine half-lives in patients with liver diseaseGut, 1973
- Effects of Chlorpromazine in Patients with Hepatic DiseaseBMJ, 1969